NVO vs. ALNY
NVO (Novo Nordisk A/S) and ALNY (Alnylam Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — NVO in Drug Manufacturers - General, ALNY in Biotechnology. Over the past 10 years, NVO returned 6.20%/yr vs 16.55%/yr for ALNY. At a 0.24 correlation, their price movements are largely independent.
Performance
NVO vs. ALNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVO achieves a -16.56% return, which is significantly higher than ALNY's -26.53% return. Over the past 10 years, NVO has underperformed ALNY with an annualized return of 6.20%, while ALNY has yielded a comparatively higher 16.55% annualized return.
NVO
- 1D
- -4.52%
- 1M
- -10.96%
- YTD
- -16.56%
- 6M
- -9.23%
- 1Y
- -42.47%
- 3Y*
- -17.53%
- 5Y*
- 1.78%
- 10Y*
- 6.20%
ALNY
- 1D
- -3.59%
- 1M
- -0.98%
- YTD
- -26.53%
- 6M
- -32.06%
- 1Y
- -2.88%
- 3Y*
- 15.25%
- 5Y*
- 13.17%
- 10Y*
- 16.55%
NVO vs. ALNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | -16.56% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
ALNY Alnylam Pharmaceuticals, Inc. | -26.53% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
Correlation
The correlation between NVO and ALNY is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Jun 2, 2004 | 0.24 |
Fundamentals
NVO:
$182.49B
ALNY:
$40.38B
NVO:
$27.42
ALNY:
$4.26
NVO:
1.50
ALNY:
68.52
NVO:
0.56
ALNY:
9.23
NVO:
0.90
ALNY:
37.55
NVO:
$327.80B
ALNY:
$4.29B
NVO:
$268.30B
ALNY:
$2.51B
NVO:
$181.54B
ALNY:
$729.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVO vs. ALNY — Risk / Return Rank
NVO
ALNY
NVO vs. ALNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NVO | ALNY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.74 | ||
| Sortino ratioReturn per unit of downside risk | -1.16 | ||
| Omega ratioGain probability vs. loss probability | 0.86 | 1.02 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | -0.77 | -0.07 | -0.71 |
| Martin ratioReturn relative to average drawdown | -1.14 | -0.12 | -1.02 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NVO | ALNY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.82 | -0.08 | -0.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.05 | 0.27 | -0.22 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.19 | 0.31 | -0.12 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.47 | 0.32 | +0.14 |
Drawdowns
NVO vs. ALNY - Drawdown Comparison
The maximum NVO drawdown since its inception was -74.70%, smaller than the maximum ALNY drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for NVO and ALNY.
Loading charts...
Drawdown Indicators
| NVO | ALNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -83.58% | +8.88% |
Max Drawdown (1Y)Largest decline over 1 year | -55.03% | -42.01% | -13.02% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -42.01% | -32.69% |
Max Drawdown (5Y)Largest decline over 5 years | -74.70% | -42.46% | -32.24% |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | -59.95% | -14.75% |
Current DrawdownCurrent decline from peak | -70.19% | -40.52% | -29.67% |
Average DrawdownAverage peak-to-trough decline | -17.77% | -30.59% | +12.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.21% | 23.22% | +13.99% |
Volatility
NVO vs. ALNY - Volatility Comparison
Novo Nordisk A/S (NVO) and Alnylam Pharmaceuticals, Inc. (ALNY) have volatilities of 9.75% and 9.94%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVO | ALNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.75% | 9.94% | -0.19% |
Volatility (6M)Calculated over the trailing 6-month period | 38.30% | 26.34% | +11.96% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.08% | 36.87% | +15.21% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.31% | 48.88% | -10.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.56% | 53.66% | -21.10% |
Dividends
NVO vs. ALNY - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 4.39%, while ALNY has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.39% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NVO vs. ALNY - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Alnylam Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. ALNY - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
ALNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 1.17B. Therefore, the gross margin over that period was 0.0%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
ALNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 268.64M and revenue of 1.17B, resulting in an operating margin of 23.0%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
ALNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 205.99M and revenue of 1.17B, resulting in a net margin of 17.7%.
Frequently Asked Questions
NVO and ALNY have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALNY has higher volatility (9.94%) compared to NVO (9.75%). In terms of maximum drawdown, NVO dropped -74.70% vs ALNY's -83.58%.
ALNY currently has the higher Sharpe Ratio (-0.08 vs -0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVO and ALNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer